Literature DB >> 16841344

Naltrexone in patients with bipolar disorder and alcohol dependence.

E Sherwood Brown1, Laura Beard, Lauren Dobbs, A John Rush.   

Abstract

Bipolar disorder is associated with very high rates of substance abuse. However, few clinical trials are reported in this population. Naltrexone is effective for alcohol dependence, but its safety and efficacy are not established in patients with bipolar disorder and alcohol dependence. A 16-week, open-label, add-on pilot study of naltrexone was conducted in 34 outpatients with bipolar disorder and alcohol dependence. Assessments included the 17-item Hamilton Rating Scale for Depression (HRSD-17), Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), and an alcohol craving scale. Alcohol use was quantified. Significant improvement was observed in the HRSD-17 and YMRS, and days of alcohol use and craving decreased significantly. Naltrexone was well tolerated. Controlled trials are warranted. Published 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841344     DOI: 10.1002/da.20213

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  8 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder.

Authors:  Andrew Naglich; Bryon Adinoff; E Sherwood Brown
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

4.  Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism.

Authors:  Jean-Michel Azorin; Charles L Bowden; Ricardo P Garay; Giulio Perugi; Eduard Vieta; Allan H Young
Journal:  Neuropsychiatr Dis Treat       Date:  2010-03-24       Impact factor: 2.570

Review 5.  Treatment of patients comorbid for addiction and other psychiatric disorders.

Authors:  Kathleen T Brady; Marcia L Verduin; Bryan K Tolliver
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

Review 6.  Bipolar disorder and alcohol use disorder: a review.

Authors:  Conor K Farren; Kevin P Hill; Roger D Weiss
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

7.  A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence.

Authors:  E Sherwood Brown; Thomas J Carmody; Joy M Schmitz; Raul Caetano; Bryon Adinoff; Alan C Swann; A John Rush
Journal:  Alcohol Clin Exp Res       Date:  2009-08-10       Impact factor: 3.455

8.  The prevalence and significance of substance use disorders in bipolar type I and II disorder.

Authors:  Michael A Cerullo; Stephen M Strakowski
Journal:  Subst Abuse Treat Prev Policy       Date:  2007-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.